Comparing Narrow Band Imaging and White Light for Detecting Colorectal Lesions
Narrow Band Imaging Versus White Light for the Detection and Miss of Sessile Serrated Lesions：a Multicenter，Random，Back-to-back Trial
This study is testing whether a special type of camera called narrow band imaging can find certain colorectal lesions better than regular white light during colonoscopy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 840 (estimated) |
| Ages | 45 Years to 85 Years |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05684328 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effectiveness of narrow band imaging (NBI) versus white light imaging (WLI) in detecting sessile serrated lesions during colonoscopy. It is a multicenter, prospective, randomized controlled trial that will assess the detection and miss rates of these lesions using both imaging techniques. Participants will undergo colonoscopy with both imaging methods to determine which is more effective in identifying these specific types of colorectal lesions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 45-85 who require screening for colorectal conditions.
Not a fit: Patients with alarming signs of colorectal cancer or those with confirmed colorectal cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection rates of sessile serrated lesions, potentially reducing the risk of colorectal cancer.
How similar studies have performed: Previous studies have suggested that narrow band imaging may improve detection rates, but this is the first randomized controlled trial specifically comparing NBI and WLI for sessile serrated lesions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients whose age are between 45-85 * Patients who have indications for screening * Patients who have signed inform consent form. Exclusion Criteria: * Patients who have undergone colonic resection * Patients with alarming signs and symptoms of colorectal cancer: hematochezia, melena, anemia, weight loss, abdominal mass, positive digital rectal examination * Patients with highly suspected or confirmed colorectal cancers by radiographic and laboratory tests * Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days before colonoscopy * Patients with inflammatory bowel diseases * Patients with hereditary colorectal cancer syndrome (including familial adenomatous polyposis). * Patients with pregnancy, severe chronic cardiopulmonary and renal disease. * Patients with therapeutic colonoscopy for existing lesions * Patients with failed cecal intubation * Patients with poor bowel preparation quality that necessitated a second bowel preparation * Patients refusing to participate or to provide informed consent
Where this trial is running
Shanghai, Shanghai
- Changhai Hospital, Second Military Medical University — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Zhaoshen Li, MD — Changhai Hospital
- Study coordinator: Zhaoshen Li, MD
- Email: li.zhaoshen@hotmail.com
- Phone: 86-021-31161365
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.